435 related articles for article (PubMed ID: 32160283)
1. Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
Lefevre PLC; Vande Casteele N
J Crohns Colitis; 2020 Aug; 14(Supplement_2):S725-S736. PubMed ID: 32160283
[TBL] [Abstract][Full Text] [Related]
2. The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
De Vries LCS; Wildenberg ME; De Jonge WJ; D'Haens GR
J Crohns Colitis; 2017 Jul; 11(7):885-893. PubMed ID: 28158411
[TBL] [Abstract][Full Text] [Related]
3. Janus Kinase Inhibitors Differentially Inhibit Specific Cytokine Signals in the Mesenteric Lymph Node Cells of Inflammatory Bowel Disease Patients.
Hindmarch DC; Malashanka S; Shows DM; Clarke AS; Lord JD
J Crohns Colitis; 2024 Apr; 18(4):628-637. PubMed ID: 37855324
[TBL] [Abstract][Full Text] [Related]
4. JAK1 inhibition and inflammatory bowel disease.
Harris C; Cummings JRF
Rheumatology (Oxford); 2021 May; 60(Supple 2):ii45-ii51. PubMed ID: 33950226
[TBL] [Abstract][Full Text] [Related]
5. The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment.
Kim JW; Kim SY
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768752
[TBL] [Abstract][Full Text] [Related]
6. Innovations in Oral Therapies for Inflammatory Bowel Disease.
Ma C; Battat R; Dulai PS; Parker CE; Sandborn WJ; Feagan BG; Jairath V
Drugs; 2019 Aug; 79(12):1321-1335. PubMed ID: 31317509
[TBL] [Abstract][Full Text] [Related]
7. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
Dowty ME; Lin TH; Jesson MI; Hegen M; Martin DA; Katkade V; Menon S; Telliez JB
Pharmacol Res Perspect; 2019 Dec; 7(6):e00537. PubMed ID: 31832202
[TBL] [Abstract][Full Text] [Related]
8. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
[TBL] [Abstract][Full Text] [Related]
9. Update on Janus kinase antagonists in inflammatory bowel disease.
Boland BS; Sandborn WJ; Chang JT
Gastroenterol Clin North Am; 2014 Sep; 43(3):603-17. PubMed ID: 25110261
[TBL] [Abstract][Full Text] [Related]
10. JAK inhibitors: current position in treatment strategies for use in inflammatory bowel disease.
Hernandez-Rocha C; Vande Casteele N
Curr Opin Pharmacol; 2020 Dec; 55():99-109. PubMed ID: 33207299
[TBL] [Abstract][Full Text] [Related]
11. Janus Kinase inhibitors in the New Treatment Paradigms of Inflammatory Bowel Disease.
Siegmund B
J Crohns Colitis; 2020 Aug; 14(Supplement_2):S761-S766. PubMed ID: 31922534
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of JAK inhibitors in Crohn's Disease.
Rogler G
J Crohns Colitis; 2020 Aug; 14(Supplement_2):S746-S754. PubMed ID: 31781755
[TBL] [Abstract][Full Text] [Related]
13. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
Nash P; Kerschbaumer A; Dörner T; Dougados M; Fleischmann RM; Geissler K; McInnes I; Pope JE; van der Heijde D; Stoffer-Marx M; Takeuchi T; Trauner M; Winthrop KL; de Wit M; Aletaha D; Baraliakos X; Boehncke WH; Emery P; Isaacs JD; Kremer J; Lee EB; Maksymowych WP; Voshaar M; Tam LS; Tanaka Y; van den Bosch F; Westhovens R; Xavier R; Smolen JS
Ann Rheum Dis; 2021 Jan; 80(1):71-87. PubMed ID: 33158881
[TBL] [Abstract][Full Text] [Related]
14. Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn's Disease.
Boland BS; Vermeire S
Gastroenterol Clin North Am; 2017 Sep; 46(3):627-644. PubMed ID: 28838419
[TBL] [Abstract][Full Text] [Related]
15. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of JAK inhibitors in Ulcerative Colitis.
Ferrante M; Sabino J
J Crohns Colitis; 2020 Aug; 14(Supplement_2):S737-S745. PubMed ID: 31879750
[TBL] [Abstract][Full Text] [Related]
17. JAK Inhibition as a Therapeutic Strategy for Inflammatory Bowel Disease.
Macaluso FS; Rodríguez-Lago I
Curr Drug Metab; 2020; 21(4):247-255. PubMed ID: 32156234
[TBL] [Abstract][Full Text] [Related]
18. JAK selectivity: more precision less troubles.
Roda G; Dal Buono A; Argollo M; Danese S
Expert Rev Gastroenterol Hepatol; 2020 Sep; 14(9):789-796. PubMed ID: 32520647
[TBL] [Abstract][Full Text] [Related]
19. The use of tofacitinib in the treatment of inflammatory bowel disease.
Weisshof R; Golan MA; Yvellez OV; Rubin DT
Immunotherapy; 2018 Aug; 10(10):837-849. PubMed ID: 29701124
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of new JAK inhibitors under development. Just more of the same?
Westhovens R
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i27-i33. PubMed ID: 30806706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]